PPH: Market Vectors Pharmaceutical ETF Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 30, 2012, 5:20 AM Pure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees. Comment! [Healthcare, Quick Ideas]
Tuesday, April 3, 2012, 10:04 AM Push comes to shove as pricey life-saving cancer drugs run up against government austerity programs and private payers unwilling to share costs for drugs that run as high as $100K a year. While Big Pharma argues that advanced technology will save money on the development side, companies such as PFE, BMY, RHHBY, and BAYRY.PK run the risk of seeing reduced profits with government-mandated price cuts for their most expensive drugs. 4 Comments [Healthcare, Quick Ideas]
Wednesday, March 14, 2012, 2:33 PM Downsizing: Only two of the top ten drugmakers increased their promotional spending last year, according to analysis from Cegedim Strategic Data. Overall, global investment on sales and marketing declined 3.4% to $92B. Comment! [Healthcare]
Wednesday, January 18, 2012, 12:01 PM Research from Frost & Sullivan breathes some life into the potential for generic drug makers with its new projections that the global market for generics could tip the scales at $231B in 2017 - repping an annual growth rate of close to 10%. The biggest drivers for the stellar growth should be blockbuster drugs that fall off their patents and the "huge potential" for copycat drug sales in emerging markets such as China, India, and Brazil. Comment! [Healthcare, Quick Ideas]
Friday, January 13, 2012, 1:35 PM Affymax (AFFY -0.3%) CEO John Orwin says the days of biotech companies seeing their share price bid up on potential is over, as investors wait it out to see if firms hash out issues with reimbursements, regulatory hurdles, and safety concerns. "There was a time when products got full value prior to launch. I think we have now swung back in the other direction." Comment! [Healthcare]
Tuesday, December 27, 2011, 2:54 PM Reuters' John Wasik identifies health care as a sector that will grow in 2012 on the strength of a long-term demographic trend that is pushing up demand for medical services, devices, and pharmaceuticals. He argues that while big pharma ETFs could see a gain, a focus on generic pharmaceutical names looks to be an even better bet as governments and companies look to cut costs. Big pharma ETFs: XPH, IHE, PJP, PPH, DRGS. Generic pharma firms: IPXL, MYL, PRX, TEVA, WPI, PRGO. Comment! [Healthcare, Quick Ideas]
Tuesday, December 27, 2011, 5:25 AM It could be a very tough year for pharmaceutical firms, which face a slew of patent expiries and new costs from healthcare reforms. Market research firm CreditSights pegs Bristol-Myers (BMY) and Eli Lilly (LLY) as likely to be next year's hardest-hit pharmas, while Abbott (ABT) and J&J (JNJ) will remain relatively sheltered. Comment! [Healthcare]
Wednesday, December 14, 2011, 7:50 AM Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity. Comment! [Healthcare, Quick Ideas, M&A]
Tuesday, December 6, 2011, 12:48 PM Sanford Bernstein analyst Tim Anderson's take on Eli Lilly (LLY +3.3%) offers a surprisingly candid view on the roulette-like risks involved in betting on drug company stocks with his estimate that LLY could clear $9B in sales of solanezumab by 2020 or misfire completely with its investment. Anderson on the sector: "Eli Lilly and several of its competitors are willing to spend hundreds of millions of dollars on what is essentially a massive lottery ticket." Comment! [Healthcare, Quick Ideas]
Friday, September 23, 2011, 1:53 PM Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy. 1 Comment [On the Move, Healthcare]
Monday, August 1, 2011, 3:56 PM Citi lowers its price target on Auxilium Pharmaceuticals (AUXL -6.6%) to $22 from $27 saying expectations on revenue from the firm's Xiaflex are too high. Earlier the firm issued its own downward guidance on FY11 revenue derived from the drug to a range of $45M-$50M from $50M-$60M. Comment! [Healthcare, On the Move]
Friday, July 8, 2011, 8:59 AM Geron (GERN) releases positive data from a clinical trial of its human embryonic stem cell-based therapy. JPMorgan initiates coverage with an Overweight rating. Shares +5.4% premarket. Comment! [On the Move, Healthcare]
Thursday, July 7, 2011, 2:36 PM Based on a long view of profit potential, a number of drug stocks trade at lower valuations than peers, SmartMoney says. After weeding out firms facing major patent issues in coming years, six winners should emerge: Glaxo (GSK +0.4%), Roche (RHHBY.PK -0.9%), Pfizer (PFE -1.9%), Sanofi (SNY -0.7%), Merck (MRK +0.8%), Novartis (NVS +0.3%). Comment! [Quick Ideas, Healthcare]
Thursday, June 30, 2011, 11:56 AM Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively. Comment! [On the Move, Healthcare]
Monday, January 17, 2011, 3:26 PM GlaxoSmithKline (GSK) will take a pharma-record £2.2B ($3.5B) charge in the fourth quarter to settle lawsuits and regulatory fines related to past sales practices. The sum outstrips Pfizer's (PFE) 2009 payment of $2.3B and relates mostly to practices between 1997 and 2004, including those around antidepressants Paxil and Wellbutrin and former diabetes blockbuster Avandia. Comment!
Tuesday, August 3, 2010, 1:42 PM The Genzyme (GENZ) play is about more than Sanofi-Aventis (SNY) looking for growth. It reflects Big Pharma's push into treating rare illnesses, with the assumption that niche diseases can be a good way to fatten margins, and product pipelines, that are under pressure elsewhere. Comment!

PPH Market Vectors Pharmaceutical ETF

PPH

Market Vectors Pharmaceutical ETF